While this impact is relevant, we are currently exploring optimized strategies to increase the mortality possibly by the combination of synergizing agents to MSC-delivered TRAIL, as we previously showed using bortezomib against a poorly TRAIL-sensitive triple-negative breast cancer [7] and as more broadly reported by Trivedi et al. [21]. The gene discussed is TNFSF10; the disease is triple-negative breast carcinoma.